Vol 6, Supplement 1 (February 2017): Translational Cancer Research


Commentary on “MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy”
Mathieu Derouet, Gail E. Darling
Association between hypomethylation of specific smoking-related CpG sites and lung cancer
Yuzuru Niibe, Atsuro Terahara, Hideomi Yamashita, Kazushige Hayakawa
Expelling the “perpetrators”: ovarian cancer cells discard miR-6126 through exosomes to promote survival
Kenta Masuda, Ahmed Ashour Ahmed
Metabolites-mitochondria-macrophages (MMM): new therapeutic avenues for inflammation and muscle atrophy
Corrado Angelini
A microRNA molecular signature of aggressive prostate cancer
Farhana Matin, Jyotsna Batra
KRAS mutations: efficacy and sensitivity of early predictive screening of cancer progression require other gene mutations in addition to KRAS
Manpreet Sambi, Myron R. Szewczuk
MOAP-1, UBR5 and cisplatin resistance in ovarian cancer
Scott T. Eblen, Amber Bradley
Immunosuppressive role of γδ T cells in cancer: the other side of the coin
Rushikesh Patil, Shalini Kashipathi Sureshbabu, Shubhada V. Chiplunkar
The vestibular approach in transoral thyroid surgery: proceedings within the clinical setting
Elias Karakas
Interaction of tumor and stromal cells in pancreatic cancer
Jochen Gaedcke, Alexander König
High dose Bacillus Calmette-Guerin (BCG) for urothelial carcinoma is trickier than expected
Mohammad R. Siddiqui, Piyush K. Agarwal
CD274 (PD-L1) genomic change: another marker for small-cell lung cancer?
Yusuke Inoue, Takafumi Suda, Haruhiko Sugimura
Cleaning up the environment in juvenile myelomonocytic leukemia
Lisa Deng, Rebecca J. Chan
Estimated risks of recurrence and mortality in lung cancer: comprehensive analysis by a population-based study
Junko Tanizaki, Hidetoshi Hayashi, Kazuhiko Nakagawa
Defining the subset of the patients in whom “Less is More” for hormone receptor-positive breast cancer: clinical risk vs. genomics risk
Yeon Hee Park
CRISPR made easy in human and murine hematopoietic precursors
Elisa ten Hacken, Michaela Gruber
Molecular heterogeneity of localized prostate cancer: more different than alike
Jeffrey J. Tosoian, Emmanuel S. Antonarakis
Early detection of lung cancer based on DNA methylation analysis in sputum and plasma
Evi Lianidou, Catherine Alix-Panabières
Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer
Alberto Ruano-Ravina, Mariano Provencio-Pulla
Inhibit a kinase to degrade a histone demethylase: a candidate therapeutic approach in glioblastoma
Alba Maiques-Diaz, Tim C. P. Somervaille
Plasma genotyping for EGFR T790M in non-small cell lung cancer: ready for clinical practice?
Melissa Bersanelli, Francesco Gelsomino, Sebastiano Buti, Michelangelo Fiorentino, Marcello Tiseo
Genetic footprints of T cell exhaustion
Marcus Buggert, Johanna Tauriainen, Annika C. Karlsson
Shelterin genes, germ line mutations and chronic lymphocytic leukemia
Irma Slavutsky
Mutations in KRAS: are they a valid biomarker for pancreatic ductal adenocarcinomas diagnosis?
Vilvapathy Narayanan, Sergey R. Konstantinov, Maikel P. Peppelenbosch
A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer
Sawsan Rashdan, David E. Gerber
Exportin 1/chromosome region maintenance 1 as a therapeutic target for lung cancer
Weimin Gao
Glioblastoma stem cells and the importance of endolysosomes to keep them in the niches
Bernard Rogister
The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT)
Theresa L. Whiteside
KDM4B under hypoxia: a new targetable pathway for epithelial ovarian cancer?
Vin Yee Chung, Ruby Yun-Ju Huang
Proton beam therapy as a rising option in treating intrahepatic cholangiocarcinoma
Jae Woo Lee, Sang Hyub Lee


Extremely low dose 18F-FDG PET imaging and its potential use for lung cancer screening
Jianhua Yan, Zhifang Wu, Sijin Li
Beyond immune suppression: the intrinsic function of PD-L1 in ovarian cancer and melanoma
Hengrui Zhu, Rugang Zhang
Neuroendocrine differentiation in prostate cancer: key epigenetic players
Karishma Gupta, Sanjay Gupta
Targeting the pyrimidine synthesis pathway for differentiation therapy of acute myelogenous leukemia
Yuqing Sun, Jay L. Hess
Oligometastatic disease in prostate cancer, a continuously changing paradigm: patient selection and treatment strategy
Andrei Fodor, Cesare Cozzarini, Claudio Fiorino, Nadia Gisella Di Muzio
Osimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Niki Karachaliou, eliciano Barron Barron, Santiago Viteri, Miguel Angel Molina, Rafael Rosell
DNA methylation biomarkers in lung cancer diagnosis: closer to practical use?
Gerd P. Pfeifer, Kemp H. Kernstine
Revealing the mutational landscape of APL
José Cervera, Miguel A. Sanz
Looking into the future (remnant liver)
Toine M. Lodewick, Frank G. Schaap, Steven W.M. Olde Damink
Gene signatures predictive of response to radiotherapy in prostate cancer: a new step towards precision medicine
Angela Lombardi, Anna Grimaldi, Michele Caraglia
Immunotherapy, checkpoint inhibitor advance to frontline non-small cell lung cancer
John Nemunaitis, Neil Senzer
Heparin-induced thrombocytopenia: new insights into the immune response
Benilde Cosmi
Subsequent treatment(s) for prostate cancer recurrence following radical prostatectomy deteriorate functional outcome and quality of life
Theo M. de Reijke
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease
Deepa Rangachari, Daniel B. Costa
Prognosis in glioblastoma: insight gained from recent prospective trials
Kara D Romano, Daniel M Trifiletti, James M Larner
Taming immune suppressor: application of myeloid-derived suppressor cells in anti-cancer gene therapy
Bhagelu R. Achyut, Ali S. Arbab


Oxaliplatin in pre-treated patients: maybe not the match point?
Chiara Caparello, Enrico Vasile, Ingrid Garajova, Asif Ali, Elisa Giovannetti
Bacillus Calmette-Guérin immunotherapy—increasing dose as a means of improving therapy?
Ratha Mahendran
Transoral thyroidectomy—from experiment to clinical implementation
Tahar Benhidjeb, Michael Stark, Isabel Gerntke, Ospan Mynbaev, Kai Witzel
Is dose-dependent response to bacillus Calmette-Guérin treatment in urothelial carcinoma?
Fabricio Racca, Rafael Morales-Barrera, Joan Carles
Metabolic sculpting of the mitochondria, cell signaling and the cancer phenotype
Martyn A. Sharpe, Nyla Ismail, David S. Baskin
A core of macrophages facilitates ovarian cancer metastases
Aida Freire Valls, Ying Shen, Thomas Schmidt
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?
Sofia Genta, Gloria Mittica, Gaia Giannone, Eleonora Ghisoni, Giorgio Valabrega
The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?
Elia Sais, Javier A. Menéndez, Joaquim Bosch-Barrera
CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
Romualdo Barroso-Sousa, Sara M. Tolaney
Beyond international prognostic index: risk stratification in diffuse large B-cell lymphoma
Hongyu Gao, Zimu Gong
The metastatic niche in the liver: tilling the soil for pancreatic cancer progression
Alexander Hann, Bruno Sainz Jr, Patrick C. Hermann
Are bladder cancer patients set at risk by minimally invasive approaches to radical cystectomy?
Günter Niegisch